Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140279 | 1.00 | ECE1 (0.31) | ECE1 | |
| SCHEMBL2142444 | 0.81 | ECE1 (0.32) | ECE1 | |
| SCHEMBL5049589 | 0.81 | ECE1 (0.32) | ECE1 | |
| SCHEMBL2582192 | 0.75 | — | — | |
| SCHEMBL4100931 | 0.75 | — | — | |
| SCHEMBL3661088 | 0.74 | ECE1 (0.33) | ECE1 | |
| SCHEMBL4955323 | 0.74 | CHRNB2 (0.37) | — | |
| SCHEMBL15428875 | 0.74 | CHRNB2 (0.35) | ECE1 | |
| SCHEMBL15428858 | 0.74 | CHRNB2 (0.35) | ECE1 | |
| SCHEMBL3665726 | 0.74 | ECE1 (0.30) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280965-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs) | KLAUS PAULINI, ET AL. | 2008-11-13 | — | — | US | disclosed |
| US-7375127-B2 | Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) | AE ZENTARIS GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20060014818-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014818-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) | GPR88, GPR34, GPR35 | ECE1 1807/4885 |
| US-20080280965-A1 | Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs) | GPR35, GPR88, GPBAR1 | ECE1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.